Q-omics provides the consensus-scored KRT18P23 profile across patient tissues and cancer cell-line models. KRT18P23 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, KRT18P23 is differentially expressed in 14, with the highest sampling consensus in STAD. Additionally, KRT18P23 RNA expression shows 10,119 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THYM, STAD, and TGCT as cancer lineages where KRT18P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P23 survival associations across molecular data types. KRT18P23 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P23 RNA expression–survival associations across cancer types. High KRT18P23 expression shows unfavorable associations in THYM, LUAD, MESO and OV, but favorable associations in THCA and BRCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THYM as the clearest survival context for KRT18P23 RNA expression.
This table summarizes KRT18P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P23 shows higher tumor expression in STAD, COAD, BRCA, LUAD, THCA and KIRP. The STAD box plot shows higher KRT18P23 RNA expression in tumor versus normal tissue (log2 FC = +0.280, t-test p < 0.001).
This table shows molecular features associated with KRT18P23 in patient tissues and cancer cell lines. In patient samples, KRT18P23 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
